FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.9.0  |  FHIR Version n/a  User: [n/a]

900000000000526001: REPLACED BY association reference set (foundation metadata concept)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module
900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)
900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)


23369 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
REPLACED BY association reference set (foundation metadata concept) Is a Historical association reference set (foundation metadata concept) true Inferred relationship Some

Members targetComponentId
Intake process Introduction procedure (procedure)
Integrated musculoskeletal release Osteopathic combined treatment method (procedure)
Intellectual disability with cataract and kyphosis syndrome Congenital disorder of glycosylation type 1q (disorder)
Intentional X-ray contrast media overdose Intentional X-ray diagnostic contrast media overdose
Intentional X-ray contrast media poisoning Intentional X-ray diagnostic contrast media overdose
Intentional antabuse overdose Intentional disulfiram overdose (disorder)
Intentional antabuse poisoning Intentional disulfiram poisoning (disorder)
Intentional chlorprothixene overdose Intentional chlorprothixene overdose (disorder)
Intentional overdose by sodium valproate Intentional valproate overdose (disorder)
Intentional pesticide product overdose Intentional pesticide product poisoning
Intentional sodium fusidate overdose Intentional fusidic acid overdose
Intentional warfarin sodium overdose Intentional warfarin overdose (disorder)
Intentional zuclopenthixol overdose Intentional chlorprothixene overdose (disorder)
Interdigital pilonidal sinus Barber's pilonidal sinus
Interferon alfa-2b 10million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 10million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 10million iu/mL injection solution 2.5mL vial Product containing precisely interferon alfa-2b 10 million unit/1 milliliter conventional release solution for injection (clinical drug)
Interferon alfa-2b 18 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 18million/iu solution Interferon alfa-2b only product
Interferon alfa-2b 18mu/vial Interferon alfa-2b only product
Interferon alfa-2b 25 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 3 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 30000000iu solution Interferon alfa-2b only product
Interferon alfa-2b 3million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 3million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 5 million iu/vial solution Interferon alfa-2b only product
Interferon alfa-2b 5million iu powder and solvent for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 5million iu powder for injection solution vial Interferon alfa-2b only product in parenteral dose form
Interferon alfa-2b 60million/iu solution Interferon alfa-2b only product
Interferon alfa-n3 human leu 5000000unt/mL injection solution 1mL vial Product containing precisely interferon alfa-n3 5 million unit/1 milliliter conventional release solution for injection (clinical drug)
Interferon beta-1a 12million iu/mL injection solution 0.5mL prefilled syringe Interferon beta-1a 30 microgram/mL solution for injection
Interferon beta-1a 24million iu/mL injection solution 0.5mL prefilled syringe Interferon beta-1a 24 million unit/mL solution for injection
Interferon beta-1a 30mcg/vial injection Product containing precisely interferon beta-1a 30 microgram/1 vial powder for conventional release solution for injection (clinical drug)
Interferon beta-1a 30mcg/vial injection solution Product containing precisely interferon beta-1a 30 microgram/1 vial powder for conventional release solution for injection (clinical drug)
Interferon beta-1a 6million iu powder and solvent for injection solution vial Interferon beta-1a only product in parenteral dose form
Interferon beta-1a 6million iu powder for injection solution vial Interferon beta-1a only product in parenteral dose form
Interferon beta-1b 100mcg injection solution Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
Interferon beta-1b 8million iu powder and solvent for injection solution vial Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
Interferon beta-1b 8million iu powder for injection solution vial Product containing only interferon beta-1b in parenteral dose form (medicinal product form)
Interim report Interim report (record artifact)
Intermediate care hospital for mentally retarded Intermediate care hospital for intellectual disability
Intermediate factor VIII fraction 250iu powder and solvent for injection solution vial Coagulation factor VIII only product
Intermediate factor VIII fraction 500iu powder and solvent for injection solution vial Coagulation factor VIII only product
Angiography of internal carotid arteries, bilateral Angiography of cervicocerebral arteries
Intermediate lobe of right lung Structure of middle lobe of right lung (body structure)
Intermediate metabolizer due to cytochrome p450 CYP2C19 variant CYP2C19 intermediate metabolizer
Intermediate metabolizer due to cytochrome p450 CYP2D6 variant Cytochrome P450 family 2 subfamily D member 6 intermediate metabolizer (finding)
Intermittent continuous positive airway pressure Positive pressure ventilation
Intermittent positive pressure ventilation Positive pressure ventilation
Intermittent positive pressure ventilation Positive pressure ventilation
Intermittent positive pressure ventilation via bag and mask Positive pressure ventilation via bag and mask (regime/therapy)
Intermittent positive pressure ventilation via endotracheal tube Positive pressure ventilation via endotracheal tube
Internal auditory meatus X-ray Plain X-ray of internal acoustic meatus of temporal bone (procedure)
Internal fixation of mandible with arch bars External fixation of mandible with arch bars (procedure)
Internal fixation of mandible with arch bars External fixation of mandible with arch bars (procedure)
Internal fixation of maxilla NEC Fixation of maxilla - internal
Internal granuloma of pulp Internal resorption of tooth
Internal haemorrhoids - other Internal hemorrhoids
Internal hemorrhoids - other Internal hemorrhoids
Internal hemorrhoids without complication Internal hemorrhoids
Internal injury NOS Injury of body cavity structure
Internal injury NOS Injury of body cavity structure
Internal mammary lymphangiogram Fluoroscopic lymphangiography of internal mammary lymph node group with contrast
Internal metabolic radiotherapy NOS Radionuclide therapy
Internal metabolic radiotherapy NOS Radionuclide therapy
Internal migration Transuterine migration (finding)
Internal oblique flap Internal oblique muscle flap
Internal resorption of crown of tooth Internal resorption of tooth
Internal support NOS Internal support
Internal support NOS Internal support
Internal unsealed radiotherapy NOS Radionuclide therapy
Internal unsealed radiotherapy NOS Radionuclide therapy
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IA1 American Joint Committee on Cancer stage IA1 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IA2 American Joint Committee on Cancer stage IA2 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IB1 American Joint Committee on Cancer stage IB1 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IB2 American Joint Committee on Cancer stage IB2 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIA1 American Joint Committee on Cancer stage IIA1 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIA2 American Joint Committee on Cancer stage IIA2 (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIB American Joint Committee on Cancer stage IIB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIIA American Joint Committee on Cancer stage IIIA (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IIIB American Joint Committee on Cancer stage IIIB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IVA American Joint Committee on Cancer stage IVA (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer (FIGO CC) stage IVB American Joint Committee on Cancer stage IVB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage 0 Carcinoma in situ of uterine cervix
International Federation of Gynecology and Obstetrics cervical cancer stage I American Joint Committee on Cancer stage I (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage II American Joint Committee on Cancer stage II (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage III American Joint Committee on Cancer stage III (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage IV American Joint Committee on Cancer stage IV (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage Ia American Joint Committee on Cancer stage IA (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage Ib American Joint Committee on Cancer stage IB (qualifier value)
International Federation of Gynecology and Obstetrics cervical cancer stage Ib occ American Joint Committee on Cancer stage IB (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IIIA American Joint Committee on Cancer stage IIIA (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IVA American Joint Committee on Cancer stage IVA (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer (FIGO EC) stage IVB American Joint Committee on Cancer stage IVB (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage I American Joint Committee on Cancer stage I (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage I A American Joint Committee on Cancer stage IA (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage I B American Joint Committee on Cancer stage IB (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage II American Joint Committee on Cancer stage II (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage III American Joint Committee on Cancer stage III (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IIIB American Joint Committee on Cancer stage IIIB (qualifier value)
International Federation of Gynecology and Obstetrics endometrial cancer stage IIIC1 American Joint Committee on Cancer stage IIIC1 (qualifier value)

Start Previous Page 96 of 234 Next End


Reference Sets

Reference set descriptor

Back to Start